STOCK TITAN

MacroGenics, Inc. - MGNX STOCK NEWS

Welcome to our dedicated page for MacroGenics news (Ticker: MGNX), a resource for investors and traders seeking the latest updates and insights on MacroGenics stock.

MacroGenics, Inc. (NASDAQ: MGNX) is a clinical-stage biopharmaceutical company based in Rockville, Maryland. The company specializes in discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. With a robust pipeline of product candidates, MacroGenics focuses on creating differentiated molecules targeting novel cancer markers, as well as 'bio-betters' designed to improve upon existing therapies.

MacroGenics' flagship product, MARGENZA, is approved for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's pipeline also includes several promising product candidates such as MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).

The company employs next-generation antibody-based technology platforms, including its proprietary DART® and TRIDENT® platforms, which enable the development of bispecific antibodies. These platforms are instrumental in the creation of MacroGenics' innovative product candidates and have led to several strategic collaborations with global pharmaceutical and biotechnology companies.

MacroGenics' recent achievements include a significant partnership with Gilead Sciences, Inc., focusing on bispecific antibodies. Under this agreement, Gilead has an exclusive option to license worldwide rights to the research program upon achieving pre-defined milestones, potentially earning MacroGenics up to $1.7 billion in target nomination, option fees, and milestone payments, plus tiered double-digit royalties on net sales.

The company is actively engaged in multiple clinical trials and anticipates sharing data from its TAMARACK Phase 2 study of vobramitamab duocarmazine for metastatic castration-resistant prostate cancer by the end of May 2024. Additionally, MacroGenics plans to release its financial results for the fourth quarter of 2023 on March 7, 2024, and for the first quarter of 2024 on May 9, 2024.

For more detailed information, please visit the company's website at www.macrogenics.com.

Rhea-AI Summary

MacroGenics, Inc. (NASDAQ: MGNX) announced updated results from a study of flotetuzumab in patients with primary induction failure (PIF) and early relapsed (ER6) acute myeloid leukemia (AML). The treatment achieved a 31.8% CR/CRh/CRi rate and a median response duration of 8.13 months. Among the 44 patients treated, many had adverse risk factors, yet 57.1% of responders received allogeneic stem cell transplants. The most common adverse event was mild cytokine release syndrome. This promising data was presented at the American Society of Hematology's Annual Meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

MacroGenics has partnered with EVERSANA to commercialize its investigational drug margetuximab for HER2-positive breast cancer in the U.S., pending FDA approval. The agreement entails shared commercialization expenses, with EVERSANA receiving revenue share payments capped at 125% of its service fees over five years. The BLA for margetuximab is under FDA review, with a decision expected by December 18, 2020. MacroGenics maintains development control, focusing on further clinical evaluations of margetuximab in various cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.69%
Tags
none
-
Rhea-AI Summary

MacroGenics, Inc. (NASDAQ: MGNX) announced the achievement of $25 million in milestones related to its collaboration with Incyte for retifanlimab, an anti-PD-1 antibody. These milestones were triggered by clinical and regulatory advancements, including the launch of the POD1UM-303 Phase 3 trial for metastatic squamous cell anal carcinoma. MacroGenics can earn up to $365 million in additional development milestones and $330 million in commercial milestones from Incyte. If approved, it could also receive royalties between 15% and 24% on global sales of retifanlimab.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

MacroGenics, a clinical-stage biopharmaceutical company focused on cancer therapies, has announced its participation in several investor conferences in November and December 2020. Key events include the Credit Suisse Annual Virtual Healthcare Conference on November 10, the Stifel 2020 Virtual Healthcare Conference on November 17, and the Evercore ISI HealthCONx Virtual Conference on December 2. Each event will involve one-on-one meetings and presentations by management. Webcasts of the conferences will be available for 30 days on MacroGenics' Investor Relations webpage.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.05%
Tags
conferences
-
Rhea-AI Summary

MacroGenics, Inc. (NASDAQ: MGNX) reported its financial results for Q3 2020, revealing total revenue of $18.2 million, nearly identical to $18.7 million in Q3 2019. R&D expenses slightly decreased to $44.7 million from $44.9 million. The net loss was $36.0 million, down from $44.6 million year-over-year. The company is progressing on pivotal studies for margetuximab, flotetuzumab, and retifanlimab, with the PDUFA action date for margetuximab set for December 18, 2020. The company held a conference call today to discuss these results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
-
Rhea-AI Summary

MacroGenics, Inc. (NASDAQ: MGNX) announces the presentation of six clinical and preclinical abstracts on acute myeloid leukemia (AML) and flotetuzumab at the 62nd American Society of Hematology Annual Meeting, occurring December 5-8, 2020. Key presentations include data on flotetuzumab as salvage therapy and its potential impact on AML. The company also highlights tebotelimab data in diffuse large B-cell lymphoma. These findings suggest growing interest in flotetuzumab as a treatment option for AML, supported by its orphan drug designation from the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.25%
Tags
none
Rhea-AI Summary

MacroGenics, Inc. (NASDAQ: MGNX) announced it will release its Q3 2020 financial results after market close on November 4, 2020. A conference call will follow at 4:30 p.m. ET to discuss these results and recent corporate progress. Interested parties can join the call by dialing the provided numbers and using Conference ID 5986584. A webcast of the call will also be available for those unable to attend live and will be accessible for 30 days post-event on MacroGenics' Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
-
Rhea-AI Summary

MacroGenics, Inc. (NASDAQ: MGNX) has published new research in Blood Advances detailing the role of TP53 abnormalities in the response to flotetuzumab, an investigational therapy for acute myeloid leukemia (AML). The study indicates that patients with TP53 mutations benefit from flotetuzumab, especially those with primary induction failure (PIF) or early relapse (ER). MacroGenics plans to enroll up to 200 patients in a pivotal study, with interim results expected at an upcoming medical conference, further supporting its development strategy in this challenging patient population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
-
Rhea-AI Summary

MacroGenics (MGNX) has published a manuscript in Molecular Cancer Therapeutics, detailing the preclinical development of MGC018, an antibody-drug conjugate targeting B7-H3 for solid tumors. The ADC shows promising antitumor activity and a favorable safety profile in preclinical models of various cancers. A Phase 1 dose expansion trial for MGC018 is currently recruiting patients with metastatic castration-resistant prostate cancer, triple-negative breast cancer, and non-small cell lung cancer. The company aims to provide updates on the study next year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.15%
Tags
none
Rhea-AI Summary

MacroGenics, Inc. (NASDAQ: MGNX) announced the publication of interim results from a Phase 1/2 trial of flotetuzumab, aimed at treating acute myeloid leukemia (AML). The trial enrolled 88 patients, revealing a 16.7% complete remission rate in those with primary induction failure or early relapse. Flotetuzumab, a bispecific DART molecule, effectively targets CD123 on leukemic cells and CD3 on T cells, leading to significant T-cell mediated responses. The company plans to expand its trial to 200 patients, with interim results expected later this year, highlighting potential for a pivotal study in this high-unmet-need population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.15%
Tags

FAQ

What is the current stock price of MacroGenics (MGNX)?

The current stock price of MacroGenics (MGNX) is $3.23 as of December 23, 2024.

What is the market cap of MacroGenics (MGNX)?

The market cap of MacroGenics (MGNX) is approximately 201.2M.

What does MacroGenics, Inc. do?

MacroGenics, Inc. focuses on discovering and developing innovative antibody-based therapeutics for treating cancer and autoimmune diseases.

What are some key products in MacroGenics' pipeline?

Key products include MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), and Retifanlimab (PD-1).

What is MARGENZA?

MARGENZA is a monoclonal antibody-based therapeutic approved for the treatment of adult patients with metastatic HER2-positive breast cancer.

What technology platforms does MacroGenics use?

MacroGenics uses proprietary technology platforms like DART® and TRIDENT® for developing bispecific antibodies and innovative product candidates.

What is the significance of MacroGenics' partnership with Gilead Sciences?

The partnership focuses on bispecific antibodies and could potentially earn MacroGenics up to $1.7 billion in milestone payments and royalties.

When will MacroGenics release its financial results for Q4 2023?

MacroGenics will release its financial results for Q4 2023 on March 7, 2024.

How can I participate in MacroGenics' conference calls?

You can register in advance via links provided on the company's website to receive dial-in information and join the conference calls.

What is the TAMARACK study?

The TAMARACK study is a Phase 2 clinical trial investigating vobramitamab duocarmazine for metastatic castration-resistant prostate cancer.

What are 'bio-betters'?

'Bio-betters' are drugs designed to improve upon existing marketed medicines in terms of efficacy, safety, or dosing.

Where can I find more information about MacroGenics?

For more detailed information, visit the company's website at www.macrogenics.com.

MacroGenics, Inc.

Nasdaq:MGNX

MGNX Rankings

MGNX Stock Data

201.16M
58.33M
2.64%
93.68%
8.12%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
Rockville